Gilead Sciences entered into licensing agreements with five generic drugmakers to make the antiviral drug Veklury (remdesivir), the first medicine shown to be effective against COVID-19, available in 127 countries.
Japan approved Gilead Sciences Inc.’s remdesivir as a treatment for COVID-19, marking the country’s first officially authorized drug to tackle the coronavirus disease.
Gilead Sciences Inc. and Galapagos NV announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis (RA) – are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier during 2019.
